HPLC HPLC column Chromolith® WP 300 RP-8

silica

Biotherapeutics, for example, bio-engineered drugs and peptide therapeutics, represent the promise of new medical treatments for the future. Production costs have been falling leading to extremely high demand for suitable analytical methods for process monitoring and quality control of these biomolecules. HPLC is the preferred method of analysis, and it is therefore important to use the right column for these larger molecules. Accurate analysis of proteins, antibodies, and large peptides requires columns with good permeability, along with better mass transfer and selectivity. In order for size-exclusion not to influence the separation, the pore size should be approximately ten times larger than the molecule being analyzed. Chromolith columns have shown great potential and superiority in comparison to standard silica. Chromolith® WP 300 columns are made of monolithic silica with a characteristic bimodal pore structure. Chromolith® WP 300 RP-8 columns have macropores with 2 μm diameter, giving a column efficiency exceeding 80,000 plates/meter. The mesopores are 30 nm (300 Å), the surface modification is Octylsilane. Chromolith® WP 300 RP-8 columns fall under the USP L7 Classification. The column efficiency is comparable to a 5 μm particle size fully porous particulate column. Chromolith® WP 300 RP-8 columns are suitable for LC-MS applications. The column dimension of 100 mm in length and 4.6 mm I.D.